ICU Medical (NASDAQ:ICUI) Posts Earnings Results, Beats Estimates By $0.60 EPS

ICU Medical (NASDAQ:ICUI) announced its earnings results on Thursday. The medical instruments supplier reported $2.03 EPS for the quarter, topping the consensus estimate of $1.43 by $0.60, FiscalAI reports. The firm had revenue of $533.30 million for the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The firm’s quarterly revenue was down 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.59 earnings per share. ICU Medical updated its FY 2025 guidance to 7.350-7.650 EPS.

ICU Medical Stock Up 8.1%

NASDAQ:ICUI traded up $10.49 during trading hours on Friday, hitting $140.16. 838,675 shares of the company’s stock traded hands, compared to its average volume of 270,664. The stock’s fifty day moving average price is $124.12 and its two-hundred day moving average price is $128.22. The firm has a market cap of $3.46 billion, a P/E ratio of -92.21 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. ICU Medical has a twelve month low of $107.00 and a twelve month high of $196.26.

Analysts Set New Price Targets

A number of research firms have recently commented on ICUI. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Piper Sandler upped their price target on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday. KeyCorp raised their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Raymond James Financial dropped their target price on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, ICU Medical presently has an average rating of “Moderate Buy” and an average target price of $181.75.

Insider Transactions at ICU Medical

In related news, CEO Vivek Jain purchased 21,929 shares of the firm’s stock in a transaction that occurred on Thursday, August 14th. The stock was acquired at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the acquisition, the chief executive officer owned 130,149 shares in the company, valued at $14,686,013.16. This trade represents a 20.26% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg acquired 1,200 shares of the stock in a transaction that occurred on Wednesday, August 27th. The shares were bought at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director directly owned 7,960 shares of the company’s stock, valued at $1,006,303.20. This represents a 17.75% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its stake in shares of ICU Medical by 75.1% in the second quarter. The Manufacturers Life Insurance Company now owns 228,909 shares of the medical instruments supplier’s stock worth $30,250,000 after acquiring an additional 98,147 shares during the last quarter. Quantinno Capital Management LP boosted its position in ICU Medical by 129.9% during the second quarter. Quantinno Capital Management LP now owns 135,142 shares of the medical instruments supplier’s stock valued at $17,859,000 after purchasing an additional 76,352 shares during the last quarter. Raymond James Financial Inc. grew its stake in ICU Medical by 64.0% in the second quarter. Raymond James Financial Inc. now owns 113,620 shares of the medical instruments supplier’s stock valued at $15,015,000 after purchasing an additional 44,323 shares in the last quarter. State Street Corp grew its stake in ICU Medical by 3.2% in the second quarter. State Street Corp now owns 927,799 shares of the medical instruments supplier’s stock valued at $122,609,000 after purchasing an additional 28,491 shares in the last quarter. Finally, Bank of America Corp DE increased its position in ICU Medical by 8.4% in the 2nd quarter. Bank of America Corp DE now owns 310,444 shares of the medical instruments supplier’s stock worth $41,025,000 after purchasing an additional 23,935 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.